Overview

Modulation of Cerebral Blood Flow Using Iron Chelators

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Phase:

Early Phase 1

Details

Lead Sponsor:

Brigham and Women's Hospital

Collaborator:

National Institute on Aging (NIA)

Treatments:

Deferoxamine